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Desensitization of human renal D1 dopamine receptors by G Dopamine produced in the kidney, mainly by proximal
protein-coupled receptor kinase 4. tubules, is an important autocrine/paracrine regulator of
Background. The D1 dopamine receptor, expressed in sev- renal sodium transport [reviewed in 1–3]. There are twoeral nephron segments, participates in the regulation of water
families of receptors belonging to the superfamily ofand electrolyte transport. Because the renal D1 receptor is
G protein-coupled receptors (GPCRs) that mediate thedesensitized in genetic hypertension, we sought to determine
the mechanism(s) of the desensitization of D1 receptors endog- actions of dopamine: the D1-like family (D1 and D5)
enously expressed in renal proximal tubules. stimulates and the D2-like family (D2, D3, and D4) inhibitsMethods. The mechanisms involved in the homologous de- adenylyl cyclase activity [1–3]. Several studies supportsensitization of the D1 receptor in human renal proximal tubule
the notion that the responsiveness of the D1-like recep-cells were studied by measuring the production of cAMP in
response to stimulation or inhibition of G protein-coupled re- tor, specifically the D1 receptor, in the renal proximal
ceptor kinase (GRK) activity and expression. Protein expres- tubule and thick ascending limb of Henle is decreased
sion was assessed by immunoblotting. in genetic hypertension [1–3]. The attenuated responsive-
Results. In human renal proximal tubule cells, the D1 agonist, ness is not caused by a decrease in renal D1-like receptorfenoldopam, increased cAMP accumulation (73 2%). Fenol-
density or D1 expression [1, 2, 4]. Rather, the D1 receptordopam pre-treatment decreased the responsiveness to subse-
quent fenoldopam stimulation (t1/2  20 min) with complete is uncoupled from its G protein/effector complex [1, 2,
desensitization at 30 minutes. Recovery occurred gradually 4–8], similar to that noted with the homologous desensiti-
(t1/2  20 min) with full recovery at 60 minutes. Forskolin pre- zation of the D1 receptor (following agonist stimulation)treatment minimally affected the fenoldopam effect, indicating
[9–14]. However, in genetic hypertension, the D1 recep-a minor involvement of protein kinase A in the homologous
tor in renal proximal tubules is desensitized even in thedesensitization process. Because GRKs are involved in the
homologous desensitization process, we determined the conse- absence of its ligand [1, 2, 4–8]. Nevertheless, an under-
quences of inhibition of GRK expression and activity. Heparin, standing of the mechanisms by which the D1 receptor isan inhibitor of GRK activity, decreased the expression of
desensitized by its ligand may yield additional insightsGRK2 and GRK4 and attenuated the desensitization of the
into the mechanism(s) that govern the ligand-indepen-D1 receptor (85  1%). Antisense oligonucleotides (GRK4 
GRK2) blunted the D1 receptor desensitization. However, the dent desensitization of the D1 receptor in hypertension.
first 20 minutes of homologous desensitization were not af- Desensitization of GPCRs involves several processes
fected by either heparin or GRK antisense oligonucleotides. including phosphorylation, sequestration/internalization,Conclusion. These studies document the critical role of
and degradation of receptor protein [15]. HomologousGRK4, relative to GRK2, in the homologous desensitization
desensitization occurs via the phosphorylation of GPCRsof D1 receptors in renal proximal tubule cells. However, the
early phase of homologous desensitization is regulated by a by a member or members of the GPCR kinase (GRK)
non-GRK-mediated pathway. family [15–18]. GRKs 1 and 7 belong to the rhodopsin
family, GRKs 2 and 3 belong to the -adrenergic recep-
tor kinase (ARK) family, and GRKs 4, 5, and 6 belong
to the GRK4 family [15–18]. GRKs are serine and threo-
nine kinases that phosphorylate GPCRs in response to
agonist stimulation. The phosphorylation of GPCRs, in-Key words: water and electron transport, hypertension, renal proximal
tubules, GRK4, sodium transport. cluding D1 receptors, leads to the binding of a member
or members of the arrestin family and uncoupling ofReceived for publication January 25, 2002
the receptor from its G protein complex, decreasing itsand in revised form March 30, 2002
Accepted for publication April 23, 2002 functional response. The phosphorylated GPCR and
-arrestin complex undergoes internalization via clathrin- 2002 by the International Society of Nephrology
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coated pits into an endosome, where it is dephosphory- selenium (5 ng/mL), insulin (5 g/mL), transferrin (5
lated and recycled back to the plasma membrane, or g/mL), hydrocortisone (36 ng/mL), triiodothyronine
degraded by lysosomes [9–20]. (4 pg mL) and epidermal growth factor (10 ng/mL). The
Several investigators have helped to decipher the path- cells were fed fresh growth medium every three days.
ways involved in D1 receptor desensitization [9–14]. When confluent, the cells were subcultured for use in
GRKs play a role in D1 receptor desensitization in that experimental protocols using trypsin (0.05%) and ethyl-
over-expression of GRK2, GRK3, and GRK5 results in enediaminetetraacetic acid (EDTA; 0.02%). For the cur-
an increase in D1 receptor phosphorylation but only the rent studies reported, cells between passages 6 and 8
over-expression of GRK5 reduces the maximal activa- were used.
tion of the D1 receptor [11]. The role of GRK4 in the
Desensitization protocolhomologous desensitization of the dopamine receptor
has not been studied. GRK4 has been reported to regu- Cultures of hPTCs from normotensive subjects were
late three GPCRs (luteinizing hormone receptor, meta- seeded at 105 cells/well in 24-well plastic plates. hPTCs
botropic glutamate receptor, M2 muscarinic receptor) were incubated at 37C in 95% air/5% CO2 for 72 hours.
and has been thought to be expressed mainly in brain, When the cells were 80% confluent, the culture media
testes, and renal medulla [17, 18, 21–24]. Following D1 were aspirated and the cells were washed twice with dex-
agonist stimulation, D1 receptors have been shown to be trose phosphate-buffered saline (DPBS). After the sec-
phosphorylated and internalized via clathrin/dynamin- ond wash, the cells were incubated at varying times and
dependent mechanisms [11–14]. However, as most of concentrations with the D1 agonist, fenoldopam, at 37C.
these studies were performed in cells heterologously At the end of the incubation period, the media were
over-expressing the D1 receptor, the mechanisms involved removed and the cells rinsed twice with fresh media. The
in GPCR regulation may vary from GPCR to GPCR cAMP responses to subsequent fenoldopam (106 mol/L,
and from cell to cell [13, 25]. Over-expression of GPCRs 30 minutes at 37C) stimulation were then measured.
may lead to coupling to G proteins not seen under “nor-
mal” circumstances [26]. Except for the studies in opos- Resensitization protocol
sum kidney (OK) cells [27, 28], the studies on D1 receptor In additional studies, the cells were treated with fenol-
desensitization were performed in cells that do not have dopam (106 mol/L) for 30 minutes at 37C. The cells
the same transport mechanisms as those noted in renal were then washed twice in DPBS prior to testing their
proximal tubule cells. Therefore, the current experiments
responses to fenoldopam (106 mol/L, 30 minutes at
were designed to study mechanisms that may be involved
37C) at the indicated times.in the homologous desensitization of D1 receptors in hu-
man renal proximal tubule cells. The role of cyclic adeno- Effect of heparin
sine monophosphate (cAMP)/protein kinase A (PKA)
The role of GRKs in the homologous desensitizationwas studied using forskolin, which directly stimulates ade-
process was evaluated using heparin, an inhibitor of GRKnylyl cyclase [28]. The role of GRKs was studied by the
activity [17, 29–31]. The cells (105 cells/24 well plate)use of heparin, an inhibitor of GRK activity [17, 29–31].
were plated and allowed to grow to 80% confluence.The role of the  ARK family of GRKs was studied by
Heparin 107 mol/L (porcine intestinal mucosa, sodiumusing antisense oligonucleotides to GRK2 and the GRK4
salt, molecular weight  3 to 5 kD) entry into the cellsfamily by using antisense oligonucleotides to GRK4.
was facilitated by co-incubating the cells with lipofectin
(5 g/mL) overnight. The cells were washed twice with
METHODS DPBS and the desensitization protocol carried out.
Human kidney
Effect of GRK2 and GRK4 antisense oligonucleotidesHuman kidneys were obtained as fresh surgical speci-
The role of GRK2 or GRK4 in the homologous desen-mens from patients (unilateral nephrectomy due to renal
sitization process was evaluated using antisense or scram-carcinoma or trauma) or kidneys not used for trans-
bled phosphorothioate/propyne oligonucleotides. Weplantation. The experiments were approved by the Uni-
chose to study GRK2 based on the report of Tiberiversity Health System Institutional Review Board.
et al [11], and GRK4 based upon our earlier studies
Renal proximal tubule cell culture indicating the importance of this GRK subtype in the
regulation of D1 receptor function [32]. The cells wereStock cultures of human proximal tubule cells (hPTC)
seeded on a 24 well plate as described above. The cellswere grown in 75 cm2 flasks as reported [8]. Briefly, the
were treated with the oligonucleotides mixed with lipo-cells were grown in serum free medium consisting of
fectin (5 g/mL) for 6 to 12 hours. After changing thea 1:1 mixture of Dulbecco’s modified Eagle’s medium
(DMEM) and Ham’s F12 medium supplemented with media, the cells were incubated in fresh media for a total
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incubation time of 48 hours. The cells were washed twice fenoldopam (106 mol/L  30 min) was used to assess
D1 receptor responsiveness. In cells pre-treated with thewith DPBS and the desensitization protocol carried out.
vehicle, fenoldopam (106 mol/L) uniformly increased
cAMP measurement cAMP accumulation almost twofold throughout the du-
ration of the study (Fig. 1A). In the cells pre-treatedThe culture media were aspirated, the cells washed
twice with DPBS, and incubated in 400 L of DPBS with fenoldopam (106 mol/L), re-exposure to fenoldo-
pam (106 mol/L) resulted in a time-dependent decreasecontaining 1 mmol/L 3-isobutyl-1-methyl xanthine in the
presence or absence of the D1 agonist, fenoldopam (total in responsiveness to subsequent fenoldopam stimulation
(Fig. 1B). For example, a 15-minute pre-treatment withreaction time 30 min). The reaction was terminated by
aspirating the media and washing the cells twice with fenoldopam resulted in a decrease in subsequent fenol-
dopam responsiveness by 27 5%, (t 20 min) whereasDPBS, and then freezing them at 80C for at least one
hour. The cells were then lysed with 0.1 N HCl and cAMP a 30-minute pre-treatment resulted in the maximum re-
duction in subsequent responsiveness (95  1%); therewas measured using a radioimmunoassay as previously
reported [5, 8]. were no further changes after 60 minutes.
Effect of inhibition of total GRK activity with heparinImmunoblotting
Well-characterized antibodies to GRK2 and GRK4	/
 Because GRKs are involved in the homologous desen-
sitization of D1 receptors [11, 32], we determined thewere purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA, USA) [18]. Cell lysates were mixed effect of inhibition of total GRK activity with low molec-
ular weight heparin. Heparin has been reported to inhi-with Laemmli sample buffer, boiled for 5 minutes, sub-
jected to electrophoresis on 7.5% sodium dodecyl sulfate bit GRK activity with a potency of: GRK5  GRK6 
GRK4  GRK2, with IC50 (nmol/L) of 1, 15, 154, and(SDS) polyacrylamide gel and transferred electrophoret-
ically to nitrocellulose membranes. Non-specific binding 150, respectively [17, 29–31]. Heparin had no effect on
cAMP accumulation under basal conditions (Table 1)was blocked with 5 to 10% nonfat dry milk in Tris/HCl/
saline/Tween-20 buffer. The membrane was then probed or with the first time exposure to fenoldopam (Fig. 1A).
Heparin also was unable to affect the early time coursewith the primary antibody (GRK2 diluted 1:750, GRK4
diluted 1:250) for one hour. After three washes, the mem- of the homologous desensitization process such that dur-
ing the first 20 minutes, the decreased ability of D1 ago-brane was incubated with peroxidase-labeled donkey anti-
rabbit IgG (Amersham, Arlington Heights, IL, USA) nist to stimulate cAMP production was indistinguishable
from the cells not treated with heparin. However, by 30with 5% nonfat dry milk for one hour. In some studies,
the antibodies were pre-adsorbed with their respective minutes, heparin was able to restore up to 85  1% of
maximum D1 agonist response (Fig. 2A). The restorationimmunizing peptide (1:5 wt/wt incubated overnight at
4C). Specific bands were visualized using enhanced chem- by heparin of the ability of fenoldopam to stimulate
cAMP accumulation was noted over a wide range ofiluminescence (ECL Western Blotting Detection Kit;
Amersham). Chinese hamster ovary cells transfected concentrations (Fig. 2B). Heparin also decreased the
expression of GRK2 and GRK4 (Fig. 2C).with the GRK4	 served as positive control for GRK4
studies. The specific bands were quantified using Quan-
Effect of inhibition of GRK2 and GRK4 activity withtiscan (Biosoft, Ferguson, MO, USA) with the total area
antisense oligonucleotidesarbitrarily set at 100% [8].
Because heparin does not exclusively inhibit GRK
Statistical analysis activity, we determined the effect of more selective inhib-
itors of GRK, namely, antisense oligonucleotides toData are expressed as mean  standard error. Signifi-
cant differences among groups and within groups were GRK2 and GRK4. GRK2 and GRK3 decreased the sen-
sitivity but not the efficacy of dopamine to stimulatedetermined by one-way analysis of variance (ANOVA)
and ANOVA for repeated measures, respectively, fol- cAMP accumulation in co-transfection studies in HEK
293 cells [11]. However, GRK3 expression was quitelowed by the Newman-Keuls or Duncan test. A P 0.05
was considered significant. weak in human renal proximal tubule cells (unpublished
studies) and, therefore, we chose to study GRK2 and not
GRK3. Although GRK5 decreased both the sensitivity
RESULTS
and efficacy of dopamine to stimulate cAMP accumula-
Time course of homologous desensitization tion in co-transfection studies in HEK 293 cells [11], we
did not study the effect of GRK5, because the GRK5Individual batches (N  3 to 5) of hPTCs were stimu-
lated with the vehicle or the D1 agonist, fenoldopam (106 band observed in our immunoblots of hPTC was not of
the correct molecular size (data not shown). GRK6 wasmol/L), at 0 (control) 20, 25, 30, 60, and 90 minutes,
and then washed. cAMP accumulation in response to not studied because the D1 agonist, fenoldopam (106
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Fig. 1. Time course of fenoldopam-induced
cAMP accumulation in human renal proximal
tubule cells. (A) Time course of fenoldopam-
induced cAMP accumulation in human renal
proximal tubule cells pre-treated with: () ve-
hicle; () heparin; () GRK2 antisense oligo-
nucleotide; () GRK2 scrambled oligonucle-
otide; () GRK4 antisense oligonucleotide;
() GRK4 scrambled oligonucleotide. cAMP
accumulation was measured after a 10, 20, 25,
or 30 minute treatment with fenoldopam 106
mol/L () or a 30 minute treatment with for-
skolin 107 mol/L (). cAMP accumulations
are greater after agonist stimulation that at 0
time, ANVR, Duncan’s test. (B) Time course
of fenoldopam-induced desensitization in hu-
man renal proximal tubule cells. Cells were
treated with fenoldopam, 106 mol/L (), for-
skolin, 107 mol/L (), or vehicle () for 15,
20, 25, 30, 60, or 90 minutes. The cells were
washed twice and cAMP accumulation in re-
sponse to a 30-minute treatment with fenol-
dopam 106 mol/L was measured. The vehicle
(time controls) in panel B represents cells that
were incubated in buffer for the indicated
times prior to measuring cAMP accumulation
in response to a 30 minute treatment with fenol-
dopam 106 mol/L. #P  0.05 vs. cells pre-
treated with vehicle or forskolin, ANOVA,
Newman-Keuls test, N  3-5/group/time pe-
riod. Data are mean  standard error. Stan-
dard errors are not depicted when they are
smaller than the symbols.
Table 1. Effect of heparin or GRK oligonucleotides on basal GRK2 antisense oligonucleotides (45  1%, N  3;
cAMP accumulation in human renal proximal tubule cells
Fig. 2A). The improvement in the stimulatory effect of
cAMP accumulation fenoldopam afforded by GRK2 and GRK4 antisense oli-
Treatment fmol/mg protein gonucleotides was evident at all concentrations (Fig. 2B).
Vehicle 10229 The ability of heparin to almost completely restore the
Heparin 10157
fenoldopam action was approximated by GRK4 but notGRK2 scrambled oligonucleotides 10089
GRK2 antisense oligonucleotides 10016 GRK2 antisense oligonucleotides (Fig. 2 A, B). The
GRK4 scrambled oligonucleotides 10099 greater restoration of fenoldopam action afforded by
GRK4 antisense oligonucleotides 10027
GRK4 than GRK2 antisense oligonucleotides (Fig. 2 A, B)
N is 2/group performed in triplicate. Data are mean  standard error. was not caused by differential effects on the expression
of their respective proteins (Fig. 2D). Thus, the inhibition
of GRK2 expression by GRK2 antisense oligonucleo-
tides was similar to the inhibition of GRK4 expressionmol/L) had no effect on GRK6 activity (unpublished
by GRK4 antisense oligonucleotides (Fig. 2D).observations). We have reported that GRK4 is important
in the regulation of D1 receptors [32], and because hepa-
Effect of forskolinrin also inhibited the expression of GRK2 and GRK4
Protein kinase A has been reported to affect homolo-(Fig. 2C), the role of GRK4 on D1 receptor function was
gous desensitization of the D1 receptor by some investi-studied. As with heparin, neither scrambled nor anti-
gators [27, 33], but not by others [28, 34]. Pre-treatmentsense oligonucleotides had any effect on cAMP accumu-
of the cells with forskolin (107 mol/L) minimally affectedlation under basal conditions (Table 1) or the first time
the stimulatory effect of fenoldopam (Figs. 1B and 2B).exposure to fenoldopam (Fig. 1A). The first 20 minutes
The effect of forskolin on cAMP accumulation also wasof homologous desensitization were not affected by
not affected by heparin, GRK2, or GRK4 antisense oli-GRK2 or GRK4 antisense oligonucleotides (Fig. 2A).
gonucleotides or fenoldopam pre-treatment (Table 2).In subsequent time points, antisense but not scrambled
oligonucleotides partially restored the stimulatory effect
Time course of resensitizationof fenoldopam on cAMP accumulation. However, the
After removal of fenoldopam and washing of the cells,effect of antisense GRK4 oligonucleotides (71  1%,
N  3) was substantially greater than that afforded by recovery occurred gradually with full recovery at 60 min-
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Fig. 2. (A) Effects of heparin, GRK2, and GRK4 oligonucleotides on the time course of fenoldopam-induced desensitization in human renal
proximal tubule cells. Cells pre-treated with heparin 107 mol/L () or vehicle () were exposed to fenoldopam 106 mol/L for indicated times
(15, 20, 25, 30, 60, 90 min). Symbols are: () GRK2 antisense oligonucleotide; () GRK2 scrambled oligonucleotide; () GRK4 antisense
oligonucleotide; () GRK4 scrambled oligonucleotide. The cells were washed twice with DPBS (37C) and then tested for their response to
fenoldopam (106 mol/L) treatment of 30 minutes, as in Figure 1. Maximum response of 100% is depicted at 0 time. Data are mean  standard
error. Standard errors are not depicted when they are smaller than the symbols. #P  0.05 vs. others, ANOVA, Newman-Keuls test, N  3/group
per time period. (B) Concentration response curves on the effect heparin, GRK2, and GRK4 oligonucleotides after a 30-minute fenoldopam-
induced desensitization in human renal proximal tubule cells. Cells treated with vehicle (), GRK4 or GRK2 scrambled oligonucleotides (),
GRK2 antisense oligonucleotides (), GRK4 antisense oligonucleotides (), or heparin () were incubated with fenoldopam (106 mol/L) for
30 minutes. The cells were washed twice in DPBS (37C) and then tested for their responses to fenoldopam (106 mol/L) treatment of 30 minutes.
The responses of the cells not pre-treated with any drug () or cells pre-treated with forskolin () are shown for comparison. Data are mean 
standard error. Standard errors are not depicted when they are smaller than the symbols. cAMP accumulation was increased by fenoldopam to a
greater extent in cells pre-treated with heparin and antisense oligonucleotides than in cells pre-treated with vehicle or scrambled oligonucleotides
and greater than basal levels (P  0.05, ANVR, Duncan’s test). *P  0.05 vs. other groups, #P  0.05 GRK2 antisense vs. other groups, ANOVA,
Newman-Keuls test, N  2-3/group/concentration. (C ) Effects of heparin on the expression of GRK2 and GRK4	/
. Symbols are: () vehicle;
() heparin. The cells were treated with heparin and lipofectin as described in the Methods section, immunoblotted for GRK2 and GRK4	/
,
and expression quantified by densitometry. Data are mean  SE. *P  0.05 vs. vehicle, t test, N  3-4/group. Inset contains representative im-
munoblots: lane 1, vehicle; lane 2, heparin. (D) Effects of GRK2 or GRK4 oligonucleotides on GRK2 and GRK4	/
 expression, respectively, in
renal proximal tubule cells. The cells were treated with () vehicle and () antisense or ( ) scrambled GRK4 oligonucleotides as described in
the Methods section. The cells were lysed, immunoblotted for GRK2 and GRK4	/
, and expression quantified by densitometry. Data are mean 
SE. *P  0.05 vs vehicle (GRK4) or others (GRK2), ANOVA, Newman-Keuls test, N  2/group. Inset contains representative immunoblots:
lane 1, vehicle; lane 2, antisense oligonucleotides; lane 3, scrambled oligonucleotides.
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Table 2. Effect of forskolin 107 mol/L on cAMP accumulation in
human renal proximal tubule cells pre-treated with vehicle,
fenoldopam, heparin or GRK antisense oligonucleotides
cAMP accumulation
Treatment fmol/mg protein
Vehicle (N  12) 6933249
Fenoldopam (N  12) 5774351
Heparin (N  5) 5701380
GRK2 antisense oligonucleotides (N  4) 703562
GRK4 antisense oligonucleotides (N  7) 5944191
N is number of experiments. Data are mean  standard error.
utes (t  40 min; Fig. 3B). The rank order potency by
which the agents enhanced the resensitization of the D1
receptor was similar to that noted with the desensitiza-
tion studies (heparin  GRK4  GRK2); scrambled
oligonucleotides had no effect on the resensitization pro-
cess (Fig. 3C). However, the enhancement of resensitiza-
tion was secondary to the prevention of the desensitiza-
tion process because the cAMP levels prior to the
resensitization studies were higher in heparin and GRK4
antisense oligonucleotides than the control or scrambled
oligonucleotide-treated cells.
DISCUSSION
There are several novel observations in our study: (1)
GRK4, a GRK that has been reported to have limited
tissue expression [17, 18, 21–24], was expressed in renal
proximal tubules; (2) GRK4, which has been reported
to regulate only a few GPCRs [17, 18, 21–24], regulated
D1 dopamine receptors; (3) heparin decreased the ex-
pression of GRK2 and GRK4; and (4) the initial process
of homologous desensitization was not inhibitable by
heparin, GRK2, or GRK4 antisense oligonucleotides.
The time course for D1 receptor homologous desensiti-
zation in hPTCs appeared to be similar to those reported
for D1 receptors in the opossum kidney (OK) cell, a Fig. 3. Time course of fenoldopam-induced resensitization of D1-like
receptor-mediated cAMP accumulation in human renal proximal tubulekidney cell line [27, 28], C6, glioma cells [12, 14, 35],
cells. (A) cAMP accumulation in response to fenoldopam (106 mol/L)retina, striatum [36], NS20Y neuroblastoma cells [9], hu- was measured after a 30-minute treatment with vehicle () or fenoldo-
man astrocytoma D384 cells [37] and D1 receptors ex- pam 106 mol/L (). *P  0.05 vs. 0 time, t test. (B) Cells treated with
fenoldopam () for 30 minutes were washed twice, incubated in mediapressed in Sf9 [38], and the internalization of D1 recep-
for 0, 15, 20, 30, 60, or 90 minutes, and then cAMP accumulation in re-tors in human embryonic kidney, HEK 293 cells [13], sponse to a 30-minute treatment with fenoldopam 106 mol/L was mea-
but was more rapid than those reported in SK-N-MC sured. #P  0.05 vs. cells pre-treated with fenoldopam and retested im-
mediately (0 time) or after incubation with media at 15 and 20 minutes,neuroblastoma cells [39] and Chinese hamster ovary cells
ANVR, Duncan’s test, N  3-5/group/time period. (C ) Cells were pre-[33]. However, while it only took one hour for complete treated with vehicle, heparin, GRK2, and GRK4 oligonucleotides as
resensitization of the D1 receptor in human renal proxi- described in the text, and the resensitization process was tested as in
panel B. Symbols are: () heparin; () GRK4 antisense oligonucleo-mal tubules, the complete resensitization of the D1 recep-
tide; () GRK2 antisense oligonucleotide; () GRK4 scrambled oligo-tor took five to six hours in C6 glioma cells [14] and 24 nucleotide; () GRK2 scrambled oligonucltotide; () vehicle. #P 
hours in NS20Y cells [9]. The difference in time course 0.05 vs. other groups, *P 0.05 vs. other groups except GRK4 antisense
oligonucleotides, ANOVA, Duncan’s test, N  2/group/time period.of desensitization and resensitization between the D1
Complete resensitization was noted in the heparin and GRK4 antisense-receptor in human renal proximal tubule cells and the treated cells at 30 minutes, ANVR, Duncan’s test. Data are mean  SE.
D1 receptor in other cells could have been due to the Standard errors are not depicted when they are smaller than the symbols.
use of dopamine in several studies and fenoldopam in
other studies, including the current report. However, the
partial agonists, fenoldopam and SKF38393 desensitized
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D1 receptors to the same extent as dopamine in glioma phorylation, -arrestin binding and receptor desensitiza-
tion. However, there are reports of the independencecells, retina, and striatum [35, 36] and less than dopamine
in human astrocytoma D384 cells [37]. Although compar- of homologous desensitization from PKA activation
[28, 34]. In our studies, direct stimulation of adenylylison of our data with other reports is hampered by differ-
ences in drugs and concentrations used by different in- cyclase activity by forskolin, which leads to the activation
of PKA, minimally affected the desensitizing effect ofvestigators, the time course for D1 receptor homologous
desensitization in renal proximal tubules was similar to fenoldopam. Thus, in the renal proximal tubule, PKA
has a small role in the homologous desensitization of D1those reported in many but not all cells. However, the
time course of resensitization was at least threefold faster receptors. D1 receptors, via calcyon, also increase PKC
activity [40] and PKC may participate in the desensitiza-than those noted in other cells, supporting the general
consensus that the desensitization/resensitization pro- tion process. We did not directly test the involvement
of PKC in our studies; however, like PKA, PKC is mainlycess is affected by the cellular environment [13, 25].
G protein-coupled receptor kinases have been impli- involved in heterologous rather than homologous desen-
sitization [22]. PKC also has been shown to desensitizecated in the homologous desensitization of GPCRs [11,
13, 15–17]. Because GRKs are involved in the desensiti- GPCRs via GRK2 [16, 41] and thus, it is not likely that
the GRK independent desensitization of the D1 receptorzation of D1 receptors [11, 32], we determined the effect
of a non-selective GRK inhibitor, heparin, in the homol- is caused by PKC.
The production of cAMP in response to the first timeogous desensitization process [17, 29–31]. Heparin de-
creased expression of GRK2 and GRK4, and reversed exposure to the D1 agonist in the first 25 minutes is almost
linear (Fig. 1A). However, homologous desensitization isD1 receptor desensitization by 85  1%. The greater ef-
fect of heparin on GRK4 than on GRK2 expression already occurring during this time period (Fig. 2). One
explanation for this apparent discrepancy is that duringis consistent with the greater sensitivity of GRK4 than
GRK2 to the inhibitory effect of heparin on GRK activ- the initial exposure to the ligand, desensitization and re-
cruitment are occurring at the same rate. Recruitment ofity [17, 29–31]; however, the mechanism by which hepa-
rin inhibits GRK expression remains to be determined. cytosolic D1 receptors in the first 15 minutes of agonist
stimulation has been described [42]. This recruitment isThe non-selective nature of heparin inhibition of
GRKs did not allow the determination of the precise role not evident in the studies of the time course of homolo-
gous desensitization, because the recruitment may haveof each member of the GRK family. Thus, in order to
determine, selectively, the role of GRK2 or GRK4 in already occurred during the first exposure and a limited
number of receptors are available for recruitment in thethe homologous desensitization of the D1 receptor, we
measured the ability of fenoldopam to stimulate cAMP subsequent exposure to the ligand. It also is possible that
the slope of the stimulation would have been steeper ifaccumulation after treatment with antisense oligonucle-
otides to these GRKs. GRK4 antisense was more effec- homologous desensitization could have been prevented
during the first exposure to the ligand. However, pretreat-tive than GRK2 antisense oligonucleotides in attenuat-
ing the fenoldopam-induced desensitization, suggesting a ment of the cells of heparin or GRK antisense oligonu-
cleotides did not alter the first time ability of the D1 agonistgreater role for GRK4 in the phenomenon of D1 receptor
homologous desensitization. This is in contrast to the to stimulate cAMP production (Fig. 1A). These data in-
dicate that the presence of a GRK-independent processimportant role of GRK2—but not GRK4—in the homol-
ogous desensitization of the -adrenergic receptor and in the early stages of homologous desensitization.
The apparent inability of GRKs to influence the firsthuman muscarinic acetylcholine receptors [20, 24].
Agonist stimulation leads to receptor desensitization 20 minutes of the homologous desensitization process is
novel. Because GRK-mediated desensitization has beenand down regulation through at least two pathways (PKA/
protein kinase C [PKC] and GRK). PKA has been re- related to clathrin, we suggest that the first 20 minutes of
the homologous desensitization process may have beenported to phosphorylate the D1 receptor at Thr268; mu-
tation of this residue minimized the homologous desen- caused by clathrin-independent mechanisms [15, 16, 19].
One such clathrin-independent desensitization processsitization process [12, 33]. A second pathway involves
receptor phosphorylation by GRK and -arrestin bind- has been ascribed to caveolin in caveolae [43–45]. Caveo-
lae are flask-like membrane invaginations, rich in caveo-ing leading to homologous desensitization of the receptor
[15–17, 29–31]. As demonstrated in neuroblastoma and lins and lipids, found in many cell types. Caveolae are
thought to be centers of signal transduction, where pro-C6 glioma cells heterologously expressing the D1 recep-
tor, agonist occupation of the receptor led to receptor teins are endocytosed separately from clathrin-coated
pits. One of the integral proteins that coat caveolae isphosphorylation, -arrestin binding, and receptor inter-
nalization [12, 13]. These two pathways may work in a caveolin. Mammals have at least three caveolin genes;
caveolin-1 (caveolin-1, caveolin-1), caveolin-2 (caveo-synergistic fashion in that receptor phosphorylation by
PKA may impair GS coupling and enhance GRK phos- lin-2, caveolin-2), and caveolin-3 [43–47]. Caveolin-1
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